Tilray Accelerates U.S. Medical Cannabis Expansion After Landmark Federal Rescheduling: Launches Tilray Medical USA to Lead Nationwide Medical Cannabis Innovation and Growth

Executive Summary

• Tilray Brands announced the formation of Tilray Medical USA, Inc. to advance U.S. medical‑cannabis operations following federal cannabis rescheduling.
• The company highlighted its global footprint (200+ products, 500,000+ patients) and plans to introduce medical‑grade cannabis products in the United States, leveraging existing compliance systems and scientific expertise.
• CEO Irwin D. Simon praised President Trump’s rescheduling decision as a catalyst for growth and signaled Tilray’s readiness to expand collaborations with U.S. healthcare providers under the new regulatory environment.

Key Details

• Regulatory Milestone: Federal cannabis rescheduling announced by the U.S. government, creating a more favorable legal framework for medical‑cannabis research and commercial activity.
• Corporate Action: Formation of Tilray Medical USA, Inc. to focus exclusively on U.S. medical‑cannabis product development, commercialization, and partnership opportunities.
• Strategic Positioning: Tilray will leverage its experience operating in over 20 international medical‑cannabis markets, existing compliance infrastructure, and scientific expertise to quickly adapt to U.S. regulatory changes.
• Product Portfolio: Over 200 registered medical‑cannabis products currently offered worldwide; the U.S. entity aims to launch medical‑grade products in targeted therapeutic formats.
• Patient Base & Research Activity: Served >500,000 registered patients globally and participated in 15+ clinical studies, covering indications such as pediatric epilepsy, cancer‑induced nausea, PTSD, chronic pain, anxiety, and more.
• Collaboration Strategy: Intent to expand partnerships with U.S. healthcare operators, physicians, hospitals, and research institutions; all collaborations will align with emerging federal medical‑cannabis guidelines.
• Leadership Quote (CEO/Chairman Irwin D. Simon): Emphasized support for the rescheduling decision, describing it as a “significant catalyst for positive change” and reaffirming Tilray’s readiness to lead in a federally legal U.S. medical‑cannabis market.

Notable Quotes

“We support President Trump’s decision to reschedule cannabis as a constructive and necessary evolution of U.S. federal policy… This landmark decision is a significant catalyst for positive change within the health, wellness, and business communities across the U.S.” – Irwin D. Simon, Chairman & CEO, Tilray Brands

All boilerplate, forward‑looking disclaimer, and “About Tilray” sections have been omitted.